HC Wainwright Lifts Earnings Estimates for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – Equities researchers at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Delcath Systems in a research report issued on Monday, October 20th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.02 per share for the quarter, up from their prior estimate of ($0.08). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.13 EPS, Q1 2026 earnings at $0.12 EPS, Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.19 EPS, FY2027 earnings at $1.45 EPS and FY2029 earnings at $2.52 EPS.

DCTH has been the subject of a number of other reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research report on Tuesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Delcath Systems in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Finally, Craig Hallum reiterated a “buy” rating and issued a $20.00 price objective on shares of Delcath Systems in a report on Tuesday. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Delcath Systems Trading Down 0.3%

Shares of Delcath Systems stock opened at $11.39 on Wednesday. The company has a fifty day moving average price of $11.05 and a 200 day moving average price of $12.40. Delcath Systems has a twelve month low of $8.87 and a twelve month high of $18.23. The stock has a market cap of $398.42 million, a price-to-earnings ratio of 227.80 and a beta of 0.84.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. The firm had revenue of $24.16 million during the quarter, compared to analysts’ expectations of $22.84 million.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors have recently added to or reduced their stakes in DCTH. Palisades Investment Partners LLC raised its stake in shares of Delcath Systems by 58.0% in the 2nd quarter. Palisades Investment Partners LLC now owns 270,310 shares of the company’s stock valued at $3,676,000 after purchasing an additional 99,226 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Delcath Systems by 13.8% in the 1st quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company’s stock valued at $17,746,000 after purchasing an additional 169,260 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Delcath Systems by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company’s stock valued at $1,497,000 after purchasing an additional 2,437 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of Delcath Systems in the 1st quarter valued at about $5,084,000. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Delcath Systems by 140.7% in the 1st quarter. Cubist Systematic Strategies LLC now owns 282,538 shares of the company’s stock valued at $3,597,000 after purchasing an additional 165,134 shares in the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.